Back to Agenda
Session 7: Predicting Safety Risk with AI, Digital Sensors, and Novel Data Sources
Session Chair(s)
Balmeet Gurm, MD
Executive Director, Therapeutic Area Lead Cardiovascular and EBs, Patient Safety, Bristol Myers Squibb, United States
Tarek Hammad, MD, PhD, MS, MSc, FISPE
Vice President, Global Head of Medical Safety, Marketed Products and PDT, PSPV, Takeda Pharmaceuticals, United States
This session shifts from tactical, vendor-focused content to more strategic content on predictive safety, implementation, and automation. It focuses on the implementation of AI and machine learning (ML), including the use of digital sensors and other novel data sources, to identify, assess, and manage safety risks. The session also looks at how health authorities are increasingly evaluating the use of AI-driven approaches for signal detection, risk assessment, and safety decision making. Speakers will share core concepts, a practical example, and the FDA perspective, so participants can see both how these approaches work and how regulators view them.
Learning Objective : - Define predictive safety and describe the data sources can be used to identify, assess, or manage safety risks
- Illustrate, using the example presented in this session, the key steps and considerations for implementing digital sensors for predicting patient safety risks
- Summarize the FDA perspective on how health authorities are evaluating AI-driven approaches for signal detection, risk assessment, and safety decision making
Have an account?